Literature DB >> 7562044

Predicting malignancy grade with PET in non-Hodgkin's lymphoma.

M Rodriguez1, S Rehn, H Ahlström, C Sundström, B Glimelius.   

Abstract

UNLABELLED: Our goal was to determine whether PET with 11C-methionine and/or 18FDG could predict malignancy grade in non-Hodgkin's lymphoma (NHL).
METHODS: Twenty-three patients with high-grade, low-grade or transformed low-grade NHL were investigated. Standardized uptake values (SUV), transport rate and mass influx values were calculated both for the whole tumor [mean regions of interest, (ROI)] and for the tumor area with the highest levels of activity, comprising four contiguous pixels within each tumor and designated as a hot spot.
RESULTS: Both 11C-methionine and 18FDG detected all tumors. In addition, 18FDG discriminated between high- and low-grade NHL, whereas 11C-methionine did not. With 18FDG, three transformed low-grade NHLs behaved in an intermediate manner. All quantitative uptake values correlated well with each other for both tracers, except for the mean ROI SUV and transport rate of 11C-methionine. Quantifications of mean ROI uptake and hot spots were strongly correlated.
CONCLUSION: The results of this study together with previous findings from other studies indicate that 18FDG but not 11C-methionine can predict malignancy grade in NHL. Further studies with a larger series of patients are needed.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7562044

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  22 in total

Review 1.  PET in lymphoma.

Authors:  Conor D Collins
Journal:  Cancer Imaging       Date:  2006-10-31       Impact factor: 3.909

Review 2.  FDG PET-CT in follicular lymphoma: a case-based evidence review.

Authors:  Stephen D Smith; Mary Redman; Kieron Dunleavy
Journal:  Blood       Date:  2014-12-19       Impact factor: 22.113

3.  Prognostic significance of the standardized uptake value of pre-therapeutic (18)F-FDG PET in patients with malignant lymphoma.

Authors:  Hossein Ahmadzadehfar; Margarida Rodrigues; Rasoul Zakavi; Peter Knoll; Siroos Mirzaei
Journal:  Med Oncol       Date:  2010-06-04       Impact factor: 3.064

4.  (18)F-FDG PET/CT with Contrast Enhancement for Evaluation of Axillary Lymph Node Involvement in T1 Breast Cancer.

Authors:  Eun Jung Kong; Kyung Ah Chun; Ihn Ho Cho; Soo Jung Lee
Journal:  Nucl Med Mol Imaging       Date:  2010-06-15

Review 5.  Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose.

Authors:  P Rigo; P Paulus; B J Kaschten; R Hustinx; T Bury; G Jerusalem; T Benoit; J Foidart-Willems
Journal:  Eur J Nucl Med       Date:  1996-12

6.  FDG-PET scans in patients with lymphoma.

Authors:  Rebecca L Elstrom; John P Leonard
Journal:  Curr Hematol Malig Rep       Date:  2008-10       Impact factor: 3.952

7.  Preliminary assessment of fluorine-18 fluorodeoxyglucose positron emission tomography in patients with bladder cancer.

Authors:  S Kosuda; P V Kison; R Greenough; H B Grossman; R L Wahl
Journal:  Eur J Nucl Med       Date:  1997-06

8.  [Large vessel vasculitis as cause of fever of unknown origin (FUO) or systemic inflammation. Diagnosis using 18-F-fluor-2-deoxy-D-glucose positron emission tomography ((18)F-FDG-PET)].

Authors:  C C Amberger; H Dittmann; D Overkamp; K Brechtel; R Bares; I Kötter
Journal:  Z Rheumatol       Date:  2005-02       Impact factor: 1.372

9.  The accuracy of positron emission tomography in the detection of posttransplant lymphoproliferative disorder.

Authors:  Daan Dierickx; Thomas Tousseyn; Annelies Requilé; Raf Verscuren; Xavier Sagaert; Julie Morscio; Iwona Wlodarska; An Herreman; Dirk Kuypers; Johan Van Cleemput; Frederik Nevens; Lieven Dupont; Anne Uyttebroeck; Jacques Pirenne; Christiane De Wolf-Peeters; Gregor Verhoef; Lieselot Brepoels; Olivier Gheysens
Journal:  Haematologica       Date:  2012-10-12       Impact factor: 9.941

Review 10.  PET/CT in oncology: for which tumours is it the reference standard?

Authors:  Conor D Collins
Journal:  Cancer Imaging       Date:  2007-10-01       Impact factor: 3.909

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.